Article Text

Download PDFPDF

125 Definitive histological evidence of myocardial fibrosis in primary degenerative mitral regurgitation: causation of symptoms?
  1. Boyang Liu1,
  2. Desley Neil2,
  3. Monisha Premchand2,
  4. Moninder Bhabra2,
  5. Ramesh Patel3,
  6. Thomas Barker3,
  7. Stephen Billing4,
  8. Nicolas Nikolaidis4,
  9. Nicola Edwards1,
  10. Rick Steeds2
  1. 1University of Birmingham
  2. 2University Hospital Birmingham
  3. 3University Hospital Coventry
  4. 4New Cross Hospital


Chronic primary mitral regurgitation (MR) exposes the left ventricle (LV) with a volume load that leads to progressive compensatory adjustments; initially LV enlargement and eccentric hypertrophy to progressive structural and functional damage. Identifying the deleterious stages of LV remodelling before the onset of irreversible dysfunction is critical to patient management and prognosis. Myocardial fibrosis with MR is proposed to develop in response to increased wall stress, but data are limited to small echo based imaging biomarkers. The aim of this prospective multi-centre study is to characterise the histological status of patients with chronic primary MR and examine associated changes in cardiac structure, function and symptom burden. 120 patients with primary degenerative MR (67% asymptomatic) were recruited prospectively. Coronary disease was excluded by angiography. All subjects underwent clinical assessment, multiparametric cardiac magnetic resonance (CMR) imaging, symptom assessment with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and cardiopulmonary exercise testing (CPET). 106 patients were referred for mitral valve surgery with the aim of collecting 3 LV biopsies per patient. Control myocardial samples were obtained from autopsies of 8 subjects who died of non-cardiac causes without signs of macroscopic or microscopic cardiac lesions.

Due to feasibility, 237 LV biopsies were collected from 85 patients. Mean collagen volume fraction (CVFmean) was elevated in MR patients compared to controls (16.1±10.1% vs, 4.3±2.7%, P=0.002), with significant CVF burden present even in the asymptomatic cohort (14.7±9.2%). Pattern of fibrosis varied between diffuse interstitial fibrosis, coarse replacement fibrosis and endocardial thickening within and between each individual biopsy sample.

Histological quantification of muscle hypertrophy demonstrated an increase in myofiber cross-sectional area in MR patients compared to controls but did not differ between asymptomatic and symptomatic patients.

There was no relationship between CVF and age, gender, ventricular volumes, measures of MR severity, LVEF or extracellular volume (ECV). Late gadolinium enhancement, present in 34% of patients, was not predictive of higher CVFmean (15.3±9.0% vs 16.5±10.8%, P=0.63). CVFmean was higher in patients with Barlow’s disease compared to FED (14±8% vs 10±11%, P=0.029) despite no difference in LV volumes, LVEF and MR severity.

Symptom burden was associated with the extent of fibrosis (MLHFQ and CVFmean, R=0.25, P=0.03), and ECV (R=0.19, P=0.06). In a multivariable regression model, increasing CVFmean and ECV both independently predicted more advanced symptoms.

In summary patients with chronic primary degenerative MR myocardial fibrosis and myofiber hypertrophy increased when still asymptomatic. t. With symptomatic MR there were further increases in CVF and ECV expansion, without continued muscle hypertrophy, suggesting that an imbalance in the fibrosis:muscle ratio may be contributory to the development of symptoms. See Figure 1 and Figure 2.

Abstract 125 Figure 1

Scanned Massons Trichrome biopsy from a NYHA class I patient, demonstrating typical examples of (A) diffuse interstitial fibrosis, (B) replacement fibrosis and (C) endocardial thickening in a NYHA class I patient.

Abstract 125 Figure 2

Relationship between CVF and myofiber cross sectional area between controls and quartiles of MLHFQ.

Conflict of Interest None

  • Mitral regurgitation
  • Myocardial fibrosis
  • Ventricular remodelling

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.